Japan's relaxing of device stability testing rules will shorten approval lag
This article was originally published in RAJ Devices
Companies seeking regulatory approval for their medical devices in Japan no longer have to submit stability testing data to establish the expiration period of the product unless the technologies are highly-specialised and novel. This move, which is much-welcomed by industry, removes one of the biggest hurdles in Japan's notoriously convoluted regulatory system and is expected to significantly shorten the country's problematic device lag, the delay in approval of new medical devices between Japan and the US/Europe.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.